Stung by patient deaths, a small Juno study points to a Goldilocks formula for CAR-T
For Juno, the hunt to find just the right mixture of T cells along with an effective regimen to prep patients for their CAR-T therapy has had a lethal history, tangling up development timelines in a way that has ceded the lead in the field to rival Kite.
But in a new, small study involving one of their most advanced CAR-Ts, an investigative team feels that they came up with just the right recipe. And that could have big implications for another CAR-T program in which Juno holds high hopes for a comeback.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.